Introduction
Voriconazole is a triazole antifungal agent active against a variety of fungi and molds, such as Candida, Aspergillus, Fusarium, Scedosporium, and Cryptococcus spps. It is particularly recommended for pulmonary invasive aspergillosis, an infection that primarily occurs in immunocompromised patients, such as those undergoing organ transplantation or with autoimmune conditions [1, 2] . Voriconazole and other triazole antifungals work by disrupting the synthesis of a compound found in fungal cell membranes called ergosterol. Disruption of ergosterol synthesis leads to damage to the fungal cell membrane and eventual fungal cell death or inhibition of fungal cell growth [3] . Although voriconazole is generally well tolerated and effective, it has a narrow therapeutic window. Drug levels that are too low can decrease efficacy, whereas those that are too high can affect tolerability and safety [2, 4] . Severe adverse events associated with voriconazole use include hepatotoxicity and effects on the central nervous system; visual disturbances are also common, particularly at higher concentrations of the drug [5] . The metabolism and clearance of voriconazole, and consequently the levels of the drug within the body, are influenced by the CYP2C19 genotype. Nongenetic factors that affect voriconazole levels include patient age, sex, liver disease, and concomitant medications [6] . Drug labels for voriconazole approved by the US Food and Drug Administration and Health Canada note that individuals who are CYP2C19 poor metabolizers (PMs) show, on average, four-fold higher drug exposure compared with normal (extensive) metabolizers (NMs) [7, 8] . However, the evidence that supports a direct association between CYP2C19 and toxicity or efficacy is limited. This review will provide an overview of the literature on the pharmacokinetics and pharmacogenetics of voriconazole. A particular focus will be on pharmacogenetics as developments in this area may provide a way to optimize dosing.
Pharmacokinetics
A schematic representation of voriconazole disposition within the body is provided in Fig. 1 . Voriconazole is extensively metabolized, with less than 2% of the original dose excreted in unchanged form [9] . The main circulating metabolite is voriconazole N-oxide, which has no antifungal activity [9, 10] . CYP2C19 is the primary enzyme responsible for the metabolism of voriconazole into voriconazole N-oxide, although CYP3A4, CYP2C9, and members of the flavin-containing monooxygenase (FMO) family also contribute [9] [10] [11] [12] ; it is estimated that ∼ 75% of the total voriconazole metabolism is mediated through the CYP enzymes, whereas the FMO family mediates the remaining 25% [11] . Voriconazole N-oxide can also be further metabolized into various less prevalent metabolites [13] . Voriconazole has the potential to act both as a substrate and as an inhibitor of the CYP2C19, CYP3A4, and CYP2C9 enzymes [9] .
Voriconazole has two other main routes of metabolism: one is the hydroxylation of the methyl group and the other is hydroxylation of the fluoropyrimidine ring [11, 13] . Figure 2 shows the chemical structures for these two hydroxylated metabolites as well as the structure for voriconazole N-oxide. Although no information is available on the enzymes involved in the hydroxylation of the fluoropyrimidine ring, hydroxylation of the methyl group is believed to occur through the action of CYP3A4 and CYP2C19 [11, 12, 14] . After hydroxylation, both metabolites form glucuronidated metabolites. In addition, the hydroxymethyl metabolite can be hydroxylated again through CYP2C19 to form dihydroxy-voriconazole; this dihydroxy metabolite can then be glucuronidated [13, 14] . Bourcier et al. [15] found that UGT1A4 is the main enzyme involved in the glucuronidation of voriconazole, although no information on its role in glucuronidation of voriconazole metabolites is available.
Pharmacogenetics
Studies on the pharmacogenetics of voriconazole have been carried out in both healthy adult individuals and immunocompromised patients; Table 1 presents an overview of these pharmacogenetic studies. Studies on healthy adults measured differences between CYP2C19 genotypes for a variety of pharmacokinetic parameters, such as clearance, area under the plasma concentration-time curve, median residence time, maximum plasma concentration (C max ), trough concentration, and elimination half-life (T 1/2 ) [14, 17, 18] . For the purposes of this review, we will occasionally group these parameters together and refer to CYP2C19 genotypes as affecting the 'metabolism' of voriconazole. Studies in immunocompromised patients focused exclusively on trough or dose-adjusted trough concentrations of voriconazole [25, 26, 37] . A major limitation of voriconazole pharmacogenetic studies is small cohort sizes; across studies on PMs, intermediate metabolizers (IMs), and ultrarapid metabolizers (UMs), approximately half of all studies included fewer than 30 individuals, the majority had fewer than 50, and only two studies included over 100 individuals [27, 44] . One meta-analysis has examined the association between CYP2C19 variants and voriconazole trough concentrations and clinical outcomes: Li et al. [45] found that PMs had increased trough concentrations compared with NMs (This paper uses the term 'normal metabolizer' in place of the term 'extensive metabolizer' in accordance with the 2016 publication by Caudle et al. [46] ) and IMs across six studies, and that IMs had increased trough concentrations compared with NMs across seven studies. They also found that PMs had increased treatment success compared with NMs (across four studies); however, no significant association with adverse effects was observed between PMs, IMs, NMs, and UMs [45] . Literature evidence for the effect of variants in other genes involved in voriconazole metabolism or concentration, such as CYP3A4 and CYP2C9, is very limited. One recent study found that dosing voriconazole on the basis of the CYP2C19 genotype leads to faster achievement of target concentrations, suggesting that pre-emptive CYP2C19 genotyping may be useful in the clinic [47] .
CYP2C19
As CYP2C19 is the primary enzyme responsible for the metabolism of voriconazole, almost all pharmacogenetic studies on the drug have focused on the contribution of CYP2C19 genotypes or the resulting metabolic phenotypes. The CYP2C19 gene is highly polymorphic, with over 30 known variant alleles (http://www.cypalleles.ki. se/cyp2c19.htm). However, the majority of individuals will carry the *1, *2, *3, or *17 alleles. The CYP2C19*1 allele is associated with a normal-functioning CYP2C19 enzyme, whereas CYP2C19*2 (rs4244285; 19154 G > A) and *3 (rs4986892; 17948 G > A) are the most common alleles associated with enzymatic loss-of-function [48] . The *2 allele varies in frequency between populations, with frequencies of ∼ 15% in Caucasians, 18% in African Americans, and 29-34% in Asians. The *3 allele is much Chemical structures of the main voriconazole metabolites. The three primary routes of voriconazole metabolism are hydroxylation of the fluoropyrimidine ring, hydroxylation of the methyl group, and N-oxidation [13] . The notation used with respect to the OH group in the 'Hydroxylation of the fluoropyrimidine ring' metabolite indicates that the location of the attachment of the OH group is variable -OH is bonded to the ring, but at an unspecified or an unknown atom of the ring. Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved. Table 1 Pharmacogenetic studies for CYP2C19 and voriconazole It is unclear from the paper whether patients with the *2/*17 and *3/*17 genotypes were included or excluded from this group of genotypes.
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, and 2-9% in Asians. Other alleles have also been associated with significantly decreased or no function (e.g.*4-*10), but they are very rare, with frequencies typically below 1% across ethnicities [48] . In addition, their functional status with specific respect to voriconazole has not been studied. The CYP2C19*17 allele (rs12248560; − 806C > T) results in increased activity of the enzyme, with frequencies of ∼ 22% in Caucasians, 19% in African Americans, 2% in East Asians, and 17% in South or Central Asians [49] . For more information on CYP2C19 alleles, their functionality, and their population frequencies, please refer to the gene-specific information table page for CYP2C19 on PharmGKB at https://www.pharmgkb.org/page/ cyp2c19RefMaterials.
On the basis of the presence of these alleles, individuals can be categorized as CYP2C19 UM, NM, IM (also referred to as heterozygous extensive metabolizers) or PMs. Individuals who are NMs are homozygous for the CYP2C19*1 allele and have a normally functioning enzyme. Those who are IMs carry one *1 allele and a loss-of-function allele (e.g. *1/*2), which produces an enzyme with reduced function. PMs carry two loss-offunction alleles (e.g. *2/*2), resulting in low or deficient CYP2C19 enzyme activity. UMs carry the *17 allele without a loss-of-function allele (i.e. *1/*17 or *17/*17), resulting in increased CYP2C19 enzyme activity [47] . Although most studies have categorized *1/*17 as an UM [27, 43] , it is occasionally grouped with the NM phenotype [50] . Individuals who carry a loss-of-function allele and a gain-of-function allele (e.g. *2/*17) are typically classified as IMs [49, 51] .
Poor metabolizers
Across 17 studies and one meta-analysis, PMs were consistently found to have reduced metabolism, leading to increased concentrations of voriconazole compared with NMs [14, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 32, 45] ; one study and a meta-analysis found that PMs had reduced metabolism compared with IMs [21, 45] . However, very little evidence exists for an effect of PM genotypes on clinical outcome. One case report noted a patient with the *2/*2 genotype who discontinued voriconazole because of highly elevated levels [23] . Another case report on an individual with the *2/*2 genotype noted that the drug was discontinued because of QTc prolongation occurring while the drug was at toxic levels. However, the study stated that the QTc prolongation might have been because of other causes, such as electrolyte abnormalities [24] . A larger study on pediatric patients reported one PM patient with high voriconazole levels who developed syndrome of inappropriate antidiuretic hormone secretion and discontinued the drug [32] . Several studies have found no statistically significant difference in the occurrence of drug toxicities (e.g. hepatotoxicity, gastrointestinal effects, photosensitization) between PMs and other metabolizer phenotypes [50, 52, 53] , including the metaanalysis previously discussed above [45] .
Intermediate metabolizers
Nine studies report an association between IMs and voriconazole metabolism and concentrations [14, 22, 26, 32, 33, 37] , although several did not carry out statistical analyses [29, 35, 36] . However, almost every study found that IMs had decreased voriconazole metabolism and increased concentrations compared with NMs. Two exceptions were a study by Shi et al. [21] , which found no significant difference in area under the curve, half-life, or clearance between IMs and NMs, and a study by Wang et al. [27] , which found no significant difference in trough concentrations between IMs and NMs, although they did find a significantly increased ratio of voriconazole trough concentrations to voriconazole N-oxide concentrations in IMs compared with NMs; no explanation is provided in these studies for the contradictory findings. As with PMs, very little evidence exists for an effect of IM genotypes on clinical outcome. One case report noted an individual with the *1/*2 genotype who required a dose reduction because of high trough concentrations [35] and another case report noted an individual with the *1/*2 genotype who had elevated concentrations accompanied by hallucinations and abnormal liver function tests. The adverse effects in the latter patient resolved after stopping voriconazole treatment, and reintroduction at a lower dose was uncomplicated [34] . A study in pediatrics reported one IM patient with liver function abnormality who required a dose reduction [32] . As stated previously under the PMs section, no additional studies have reported a statistically significant association between CYP2C19 genetic variations and voriconazole-related adverse events. Most reports to date have been of singular patients or case reports.
Ultrarapid metabolizers
Ten studies have examined the effect of UM genotypes on the metabolism and plasma concentrations of voriconazole [18, 26, 27, [36] [37] [38] [39] [40] [41] 43] , with five focusing exclusively on the *1/*17 genotype [18, 27, 39, 40, 43] . One study found that those with the *1/*17 genotype had statistically significantly increased clearance compared with NMs [18] . Two additional studies also found that those with the *1/*17 genotype had decreased concentrations of voriconazole compared with NMs or PMs, but neither carried out statistical analyses [27, 43] . In addition, two case reports noted subtherapeutic or undetectable levels of the drug in those with the *1/*17 genotype [39, 40] . However, in one of these reports, a patient with chronic granulomatous disease had complicated results. The patient had exceptionally high voriconazole concentrations upon initial assessment, but subsequent voriconazole concentrations were so low as to be undetectable; the authors suggest that this may be the result of CYP450 enzyme downregulation by inflammation [39] . In contrast to these reports, a study in pediatric patients by Hicks et al. [26] found no statistically significant difference in voriconazole dose-adjusted trough concentrations between those with the *1/*17 genotype and those with the *1/*1 genotype.
Literature evidence on the effect of the *17/*17 genotype on voriconazole levels is sparse. However, the same pediatric study by Hicks et al. found that those with the *17/*17 genotype did have statistically significantly lower dose-adjusted trough concentrations of voriconazole compared with those with the *1/*1 genotype (four patients with this genotype were included in the study) [26] . Two case reports support this association: one describing an individual who had undetectable levels of drug, prompting a discontinuation of voriconazole and switch to an alternative drug [38] , and the other describing an individual with acute leukemia who had a lack of response and a failure to achieve therapeutic concentrations, also prompting discontinuation and switch to caspofungin [42] . However, in the former case study, the authors noted that the patient was comedicated with carbamazepine, a known CYP2C19 inducer, and therefore the individual contributions of the genotype and comedication cannot be distinguished [38] . In the latter study, the authors state that comedications and disease-induced modulation of CYP2C19 and CYP3A4 cannot be excluded as explanations for the low voriconazole concentrations [42] .
In addition, one study in lung transplant patients found that those with the *1/*17 or *17/*17 genotypes had a statistically significantly increased risk for squamous cell carcinoma (SCC) when receiving voriconazole [44] . SCC can lead to numerous cutaneous lesions, which may require surgery, and in some cases, may be fatal; voriconazole use is associated with a 73% increased risk of the disease in lung transplant recipients [54] . The authors of the study on CYP2C19 UMs and SCC suggest that the increased risk of SCC may be because of a link between the voriconazole N-oxide metabolite and DNA damage [44] .
Genotype-directed dosing of voriconazole
Lamoureux et al. [37] sought to determine the impact of CYP2C19 genotypes on the dose required to attain therapeutic voriconazole plasma concentrations in a cohort of 35 patients. They found that the therapeutic dose requirement did not differ between NMs and IMs or PMs. However, UMs had a significantly greater dose requirement compared with NMs and also showed an ∼ 1.5-fold greater dose requirement compared with IMs or PMs (UMs: 4.76 0.47 mg/kg twice daily vs. IMs/PMs: 3.03 0.36 mg/kg twice daily) [37] . A recent study by Teusink et al. [47] compared the standard dosing of voriconazole with genotype-directed dosing. A pilot study followed 25 individuals undergoing hematopoietic stem cell transplantation who received an initial dose of voriconazole of 5 mg/kg twice daily, irrespective of genotype. Their doses were then adjusted until they were within the target therapeutic range of 1-5.5 ug/l. A subsequent study genotyped 20 individuals for CYP2C19 *2, *3, and *17 before administering voriconazole, and adjusted the initial voriconazole dose on the basis of their genotype as follows: IMs or unknown metabolizers received 6 mg/kg/dose every 12 h, and NMs or UMs received 7 mg/kg/dose every 12 h. No PMs were present and only one UM (*1/*17) was present in the genotype-directed dosing arm. Doses were then adjusted, as in the pilot study, until they were within the target range.
Comparison of the genotype-directed dosing arm with the standard dosing arm showed that patients in the genotypedirected dosing arm took a median of 6.5 days to achieve the target therapeutic range, whereas patients in the standard dosing arm took a median of 29 days, a statistically significant difference [47] .
Other genes
Although CYP3A4, CYP2C9, and members of the FMO family all contribute toward the metabolism of voriconazole, there is very limited evidence for an association between variants within the genes that encode these enzymes and concentrations or pharmacokinetic parameters of voriconazole. One study found that those with the AG genotype at rs4646437 in the CYP3A4 gene had significantly higher concentrations of voriconazole compared with those with the GG genotype [55] . The functional role of the rs4646437 single nucleotide protein is yet to be determined, but contrasting findings have been reported in studies involving tacrolimus, cyclosporine, and finasteride -those with the GG genotype were observed to have the highest concentrations of these drugs, followed by the AG genotype and then the AA genotype [56, 57] . CYP2C9 also plays a role in voriconazole metabolism, but a single case report on an individual with the *2/*2 (PM) genotype found similar pharmacokinetic parameters when compared against healthy volunteers with the *1/*1 genotype [58] . To date, there are no studies investigating the effect of FMO family variants on voriconazole metabolism or response.
Conclusion
Although a reasonable amount of literature evidence supports an association between the CYP2C19 genotype and voriconazole exposure, these supporting studies are mostly underpowered. Larger studies may be necessary to ascertain a more definitive link between the gene and drug. However, the feasibility of such large studies can be hindered by the difficulty of finding enough patients who are PMs, IMs, or UMs; international collaborations could aid in recruiting patients with diverse CYP2C19 phenotypes. In addition, findings connecting CYP2C19 polymorphisms to voriconazole clinical outcomes and adverse events have not been consistent. Hence, more studies are needed to address this potential association. Although one study did prospectively genotype CYP2C19 and showed a faster achievement of target voriconazole concentrations, this conclusion is limited because of the study's small size, lack of PMs, and having only a single UM participant in the genotype-directed dosing arm [47] . These issues with the current body of literature warrant further research into this topic, given the high morbidity and mortality rates of failed antifungal therapy in immunocompromised patients. Recently published guidelines by the Clinical Pharmacogenetics Implementation Consortium [59] providing therapeutic recommendations for voriconazole on the basis of the CYP2C19 genotype may help clinicians in delivering more accurate dosing, possibly preventing delays in treatment optimization or unwanted adverse events.
